Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The comparative effect of combination chemotherapy with Paclitaxel (Taxol) and Gemcitabine vs Taxol and Vinorelbine on survival in non-operable non-small cell lung cancer stage IIIBw and IV, PS : 0, 1. A Phase III randomized study.

Trial Profile

The comparative effect of combination chemotherapy with Paclitaxel (Taxol) and Gemcitabine vs Taxol and Vinorelbine on survival in non-operable non-small cell lung cancer stage IIIBw and IV, PS : 0, 1. A Phase III randomized study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Gemcitabine; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Sep 2010 Primary endpoint 'Overall-survival-rate' has not been met, according to Annals of Oncology publication.
  • 29 Sep 2010 Primary endpoint 'Overall-survival-duration' has not been met, according to Annals of Oncology publication.
  • 29 Sep 2010 Results were published in the Annals of Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top